Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Retained Earnings: 2022-2024

Historic Retained Earnings for Entrada Therapeutics (TRDA) over the last 3 years, with Dec 2024 value amounting to -$129.3 million.

  • Entrada Therapeutics' Retained Earnings fell 79.26% to -$233.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$233.9 million, marking a year-over-year decrease of 79.26%. This contributed to the annual value of -$129.3 million for FY2024, which is 33.66% up from last year.
  • Per Entrada Therapeutics' latest filing, its Retained Earnings stood at -$129.3 million for FY2024, which was up 33.66% from -$195.0 million recorded in FY2023.
  • In the past 5 years, Entrada Therapeutics' Retained Earnings ranged from a high of -$129.3 million in FY2024 and a low of -$195.0 million during FY2023.
  • For the 3-year period, Entrada Therapeutics' Retained Earnings averaged around -$170.9 million, with its median value being -$188.3 million (2022).
  • As far as peak fluctuations go, Entrada Therapeutics' Retained Earnings decreased by 3.55% in 2023, and later skyrocketed by 33.66% in 2024.
  • Over the past 3 years, Entrada Therapeutics' Retained Earnings (Yearly) stood at -$188.3 million in 2022, then fell by 3.55% to -$195.0 million in 2023, then skyrocketed by 33.66% to -$129.3 million in 2024.